Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Theralase Technologies Inc. (TLTFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1706+0.0056 (+3.39%)
At close: 3:25PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1650
Open0.1622
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1622 - 0.1771
52 Week Range0.0900 - 0.2600
Volume35,410
Avg. Volume87,784
Market Cap34.849M
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings DateNov 25, 2021 - Nov 29, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TLTFF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • THERALASE TECHNOLOGIES INC
    Daily – Vickers Top Buyers & Sellers for 10/18/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • Simply Wall St.

    We're Hopeful That Theralase Technologies (CVE:TLT) Will Use Its Cash Wisely

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • GlobeNewswire

    Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter

    Study II Clinical Data (Preliminary)* Study II Clinical Data (Preliminary)* TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses has releas

  • GlobeNewswire

    Theralase Announces Leadership Transition

    TORONTO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today the departure of its Chief Executive Officer (“CEO”), Shawn Shirazi effective August 20, 2021. Effective August 23, 2021, John Trikola will assume the role of Chief Operating Officer (“

Advertisement
Advertisement